UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc (LXEO)
2.50 x 1 2.74 x 3
Post-market by (Cboe BZX)
2.71 +0.43 (+18.86%) 04/17/25 [NASDAQ]
2.50 x 1 2.74 x 3
Post-market 2.56 -0.15 (-5.54%) 16:21 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.25
Day High
2.73
Open 2.26
Previous Close 2.28 2.28
Volume 608,200 608,200
Avg Vol 1,430,830 1,430,830
Stochastic %K 39.48% 39.48%
Weighted Alpha -81.31 -81.31
5-Day Change +0.54 (+24.88%) +0.54 (+24.88%)
52-Week Range 1.45 - 19.50 1.45 - 19.50
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,964
  • Shares Outstanding, K 33,197
  • Annual Sales, $ 0 K
  • Annual Income, $ -98,330 K
  • EBIT $ -106 M
  • EBITDA $ -105 M
  • 60-Month Beta 1.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.72

Options Overview Details

View History
  • Implied Volatility 695.76% ( +563.40%)
  • Historical Volatility 209.22%
  • IV Percentile 98%
  • IV Rank 100.00%
  • IV High 695.76% on 04/17/25
  • IV Low 128.14% on 04/15/25
  • Put/Call Vol Ratio 1.83
  • Today's Volume 17
  • Volume Avg (30-Day) 139
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 1,360
  • Open Int (30-Day) 1,012

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.80
  • Number of Estimates 3
  • High Estimate -0.78
  • Low Estimate -0.83
  • Prior Year -0.77
  • Growth Rate Est. (year over year) -3.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.45 +86.90%
on 04/07/25
Period Open: 3.11
4.59 -40.96%
on 03/26/25
-0.40 (-12.86%)
since 03/17/25
3-Month
1.45 +86.90%
on 04/07/25
Period Open: 5.07
6.04 -55.13%
on 02/06/25
-2.36 (-46.55%)
since 01/17/25
52-Week
1.45 +86.90%
on 04/07/25
Period Open: 12.26
19.50 -86.10%
on 07/11/24
-9.55 (-77.90%)
since 04/17/24

Most Recent Stories

More News
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

LXEO : 2.71 (+18.86%)
Pharma Frenzy: Volatility Ignites Biotech Sector

Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.

TNXP : 15.71 (-0.95%)
LXEO : 2.71 (+18.86%)
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.

LXEO : 2.71 (+18.86%)
IBB : 118.29 (+0.42%)
VTI : 258.75 (+0.21%)
IWM : 186.48 (+0.82%)
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

LXEO : 2.71 (+18.86%)
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LXEO : 2.71 (+18.86%)
Lexeo Therapeutics Appoints Dr. Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics appoints Dr. Kyle Rasbach as CFO, enhancing leadership ahead of key developments in gene therapy.Quiver AI SummaryLexeo Therapeutics has appointed Dr. Kyle Rasbach as its new Chief Financial...

LXEO : 2.71 (+18.86%)
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

LXEO : 2.71 (+18.86%)
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

LXEO : 2.71 (+18.86%)
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

LXEO : 2.71 (+18.86%)
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

LXEO : 2.71 (+18.86%)

Business Summary

Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.

See More

Key Turning Points

3rd Resistance Point 3.36
2nd Resistance Point 3.04
1st Resistance Point 2.88
Last Price 2.71
1st Support Level 2.40
2nd Support Level 2.08
3rd Support Level 1.92

See More

52-Week High 19.50
Fibonacci 61.8% 12.60
Fibonacci 50% 10.48
Fibonacci 38.2% 8.35
Last Price 2.71
52-Week Low 1.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro